THC Receives Dried Marihuana order from Germany, Appoints New Director, Settles Debt for Shares

**THC.CSE                                             THCBF – OTC                                              TFHC.F**

**Vancouver, B.C. – (June 22, 2017)** THC Biomed Intl Ltd. (“**THC**”) is pleased to announce that it has received an order to export Dried Marihuana to Germany. THC has initiated the process to meet regulatory requirements to export to the European Union.

THC is excited to begin to claw into, what is anticipated to be more than a billion-dollar International Cannabis Market.

THC currently offers 29 different Genetic strains for sale and has the largest variety of Genetic strains available in Canada to home growers.

“THC intends to soon begin selling dried Marihuana as an interim supply to registered home growers at $4.20 per gram. We believe this would be the lowest price ever offered to medical patients in Canada,” commented John Miller, President and CEO of THC.

“We are pleased to offer this wholesale-type pricing to our fellow growers. The home growing market is expected to expand rapidly in the event recreational Marihuana is introduced,” said Mr. Miller.

THC is also pleased to announce that Dr. Ashish Dave has consented to join the Board. He was appointed as a Director on June 21, 2017. Dr. Dave is a scientist who has previously consulted for THC. Dr. Dave has a PHD in plant tissue culture and a Master’s Degree in botany.

THC has also settled $58,596 of debt obligations for consulting services through the issuance of 133,172 common shares of THC at a deemed price of $0.44 per share

About THC

THC is an authorized licensed producer of dried Marihuana for Medical Purposes and fresh Marihuana and Cannabis oil – production only. THC’s vision is to be on the leading edge of scientific research and development of products and services related to the medical Cannabis industry while creating a standard of excellence. As the industry develops, it will become more important to focus on scientific research and development of products and services related to medical Cannabis. Management believes THC is well positioned to be in the forefront of this rapidly growing industry.

Please visit our website for a more detailed description of our business and services available. [www.thcbiomed.com](http://www.thcbiomed.com/)

**President and CEO:**

John Miller

THC Biomed Intl Ltd.  
T: (250) 870-2512  
E: [info@thcbiomed.com](mailto:info@thcbiomed.com)

**Forward-Looking Information:**

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) there will be a more than billion dollar International Cannabis Market THC has the largest variety of Genetic strains available in Canada to home growers (b) THC will sell dried Marihuana to registered home growers at $4.20 per gram (c) $4.20/gram would be the lowest price ever offered to medical patients in Canada (d) The home growing market is expected to expand rapidly once recreational Marihuana is introduced and (e) recreational Marihuana may be introduced. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.